Related Experiment Videos

Acidic fibroblast growth factor-Pseudomonas exotoxin chimeric protein elicits antiangiogenic effects on endothelial

J R Merwin1, M J Lynch, J A Madri

  • 1Molecular and Cellular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut.

Cancer Research
|September 15, 1992
PubMed

Insights

Acidic fibroblast growth factor fused to Pseudomonas exotoxin (aFGF-PE) shows anti-angiogenic and cytotoxic effects on microvascular endothelial cells. This chimeric toxin inhibits protein synthesis and migration, demonstrating potential as an anti-cancer agent.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chimeric toxins like acidic fibroblast growth factor fused to mutant Pseudomonas exotoxin (aFGF-PE) show tumor cell cytotoxicity.
  • Limited data exists on the effects of aFGF-PE on endothelial cells, crucial for understanding its therapeutic potential.

Purpose of the Study:

  • To investigate the anti-angiogenic potential of aFGF-PE664GluKDEL, a specific aFGF-PE fusion protein.
  • To evaluate the effects of aFGF-PE on microvascular endothelial cell (RFC) protein synthesis, angiogenesis, and migration.

Main Methods:

  • Protein synthesis inhibition assays using RFCs.
  • 3-dimensional collagen gel cultures to assess angiogenesis and cell migration, with or without transforming growth factor beta 1.
  • Cell viability analysis and competition assays using anti-aFGF antibodies.

Main Results:

  • aFGF-PE significantly inhibited RFC protein synthesis at concentrations >100 ng/ml, with up to 83% inhibition at 1000 ng/ml.
  • aFGF-PE blocked transforming growth factor beta 1-induced in vitro angiogenesis and prevented RFC migration in 3D cultures.
  • Cell viability assays revealed a dose-dependent toxic effect of aFGF-PE (10-90% cell death), and antibody competition reversed inhibitory effects by 89%.

Conclusions:

  • aFGF-PE exhibits specific in vitro cytotoxic, anti-angiogenic, and antimigratory effects on microvascular endothelia.
  • These findings support the potential of aFGF-PE as an anti-angiogenic agent for cancer therapy.

Related Concept Videos